Hypertonic saline has been shown to reduce the production of MMPs, such as MMP‐9 and MMP‐13, in mouse models of acute lung injury, thereby reducing disease progression and inflammation; an open‐label clinical trial is currently underway to evaluate efficacy in post‐traumatic acute lung injury (Table 1) 86, 87, 88. This evidence concerns the gene MMP13 and injury.